OKLO heads into its May 12 earnings debut with founders selling at the top, short sellers entrenched, and a stock that has surged 56% in a single month.
The loudest signal in the data is insider activity. CEO Jacob DeWitte, COO Caroline Cochran, and CFO Richard Bealmear all sold shares on May 1 — the same day — at prices between $69 and $71. DeWitte alone offloaded over 100,000 shares across four transactions totalling roughly $7 million. Cochran sold 100,000 shares for more than $7 million. The CFO added another $1.1 million in sales. These are founders and executives reducing exposure at or near the stock's recent highs, just eight trading days before the company's first quarterly earnings report as a public company — a detail worth noting.
The short side tells a different kind of story. Short interest is elevated at 19% of the free float, with roughly 29.7 million shares short — and it has climbed 31% over the past month, broadly in line with the stock's own rally. Bears are clearly not capitulating into the price move. The ORTEX short score sits at 69.8 out of 100, ranking in the 3rd percentile of the universe — meaning almost no stock carries a higher short score. Borrow availability has tightened meaningfully, with utilization running at 85% against a 52-week peak of 97.7%, though the cost to borrow remains modest at under 1% — suggesting short sellers can hold positions cheaply for now.
Options positioning has edged more defensive into the print. The put/call ratio is 0.76, running about 1.6 standard deviations above its 20-day average of 0.68. That's not extreme — the 52-week high is 1.15 — but the directional shift is consistent with investors adding downside protection as the earnings date approaches. Two bellwether-adjacent initiations arrived last month: HSBC started at Buy with a $96 target and Tigress Financial at Buy with $130. Both sit below where Goldman Sachs and UBS landed after trimming their targets in March — Goldman cut to $65, UBS to $60 — moves that followed the stock's prior earnings reactions, which produced a 5% one-day drop and an 8% five-day loss in March. The mean analyst target has since recovered to $91, implying about 26% upside from the current price.
The bull case rests on Oklo's positioning as a first-mover in small modular reactors, its fuel recycling ambitions, partnerships with national labs, and a claimed pipeline of 12 GW over 20 years — none of which is generating revenue yet. Bears point to exactly that gap: no revenue, commercialization still ahead, heavy execution risk, and a stock priced as though the reactor is already running. The May 12 print is therefore less about earnings — there are none to speak of — and more about whether management's project timeline, regulatory progress, and forward guidance can justify a stock that has more than doubled from its April lows while its own founders were sellers all the way up.
See the live data behind this article on ORTEX.
Open OKLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
